Stephan Grupp Laboratory News Updates
1 - 6 of 6
FDA Approves Personalized Cellular Therapy for Advanced Leukemia Developed by University of Pennsylvania and Children’s Hospital of Philadelphia
Published on
This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.
Younger T Cells May Improve Immunotherapy for Children’s Cancer
Published on
CHOP is working to improve personalized cell therapy for children. Using younger T cells may offer better results against certain types of leukemia and lymphoma.
Benefits Persist in T Cell Therapy for Children With Relapsed Leukemia
Published on
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study.
Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied
Published on
Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy, CTL019.
Cell Therapy for ALL Receives Breakthrough Therapy Designation
Published on
A personalized immunotherapy has been awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia.
CHOP Leads Pediatric Cancer Research Dream Team
Published on
The first ever pediatric “Dream Team” dedicated to creating new treatments for childhood cancers will be led CHOP's own John Maris, MD.